|Bid||0.00 x 1300|
|Ask||0.00 x 800|
|Day's Range||0.1118 - 0.1230|
|52 Week Range||0.0800 - 0.3900|
|Beta (3Y Monthly)||0.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||Dec 13, 2018 - Dec 17, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.40|
NEW YORK , Jan. 13, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
NEW YORK , Jan. 9, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Ohr Pharmaceutical, Inc. ("OHRP" ...
NEW ORLEANS , Jan. 8, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger ...
Do you own shares of Ohr Pharmaceutical, Inc. (NASDAQ CM: OHRP)? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Ohr Pharmaceutical, Inc. (“Ohr” or the “Company”) (NASDAQ CM: OHRP) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to merge with NeuBase Therapeutics, Inc. (“NeuBase”).
NEW YORK, Jan. 04, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of OHR Pharmaceutical, Inc. (NASDAQ: OHRP) on behalf.
A move that stands to fast-forward a new entry into Pittsburgh’s public company ranks by mid-year has benefits for both parties. South Side startup NeuBase Therapeutics’ top executive said a reverse merger with a struggling, publicly traded pharmaceutical company will speed delivery of its treatments for genetic diseases. Dietrich Stephan, NeuBase CEO and founder, said during a joint press conference on Thursday that the merger between NeuBase and Ohr Pharmaceutical Inc. “accelerates getting our technologies into the clinic for those who desperately need them.” For Ohr, which announced the pending deal on Wednesday, it culminates a year-long evaluation of strategic alternatives that Jason Slakter, president and CEO, described as “exhausting.” But he believes the merger opens opportunities to create value for stockholders.
NEW YORK, Jan. 04, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ohr Pharmaceutical, Inc. (“Ohr” or.
PITTSBURGH, Jan. 4, 2019 /PRNewswire/ -- LifeX™ today announced that its portfolio company NeuBase Therapeutics, Inc. has entered into a definitive merger agreement with Ohr Pharmaceutical, Inc. (OHRP) and that Dietrich A. Stephan, Ph.D., the former chief executive officer of LifeX, will lead the combined company as its CEO. In less than a year, NeuBase has gone from an idea to a company with a clear path to a NASDAQ list, validating the LifeX approach of quickly translating technology from the bench to the bedside.
CORAL GABLES, FL / ACCESSWIRE / January 3, 2019 / The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the ...
Ohr Pharmaceutical, Inc. (“Ohr”) (OHRP) announced today that it has entered into a definitive merger agreement with NeuBase Therapeutics, Inc. (“NeuBase”), under which the stockholders of NeuBase would become the majority holders of the combined company. The proposed merger will create a public company focused on advancing NeuBase’s peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations.
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
LONDON, UK / ACCESSWIRE / July 13, 2018 / If you want a free Stock Review on OHRP sign up now at www.wallstequities.com/registration. For today, WallStEquities.com observes Auris Medical Holding AG (EARS), NewLink Genetics Corp. (NLNK), OHR Pharmaceutical Inc. (OHRP), and Omeros Corp. (OMER). The industry includes the manufacturing and marketing of drugs as a result of direct research and development.
Stock Research Monitor: NLNK, OHRP, and ONCS LONDON, UK / ACCESSWIRE / June 12, 2018 / If you want a free Stock Review on OMER sign up now at www.wallstequities.com/registration . On Monday, benchmark ...
NEW YORK , June 4, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, announces that it has been appointed as Lead Counsel in Khanna v. Ohr Pharmaceutical, Inc., et al. ...
NEW YORK, NY / ACCESSWIRE / May 1, 2018 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of Ohr Pharmaceutical, ...
NEW YORK, NY / ACCESSWIRE / April 9, 2018 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of Ohr Pharmaceutical, ...
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ohr Pharmaceutical, Inc. who purchased shares between June 24, 2014 and January 4, 2018.
NEW YORK, April 5, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ohr Pharmaceutical, Inc. ("Ohr" or the "Company") (OHRP) of the April 16, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Ohr stock or options between June 24, 2014 and January 4, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/OHRP. There is no cost or obligation to you.
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Ohr Pharmaceutical, Inc.
The following statement is being issued by Levi & Korsinsky, LLP:
NEW YORK , March 20, 2018 /PRNewswire/ -- BioScrip, Inc. (BIOS) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with BioScrip's disclosure that it ...